Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting

Allogeneic hematopoietic cell transplantation (HCT) is the most potent postremission therapy in AML [1, 2], and is widely used in younger patients with intermediate or adverse risk cytogenetics [3]. Transplant decisions are mainly based on the cytogenetic and molecular risk group, age, comorbidity, response to therapy and on the availability of a suitable donor [4]. AML is in more than one fourth of all cases secondary (s-AML), arising after previous chemo- and/or radiotherapy, i.e., therapy-related (t-AML), or developing after an antecedent myeloid disease (AHD-AML), such as myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN).

Source: Biology of Blood and Marrow Transplantation - June 5, 2019 Category: Hematology Authors: Christer Nilsson, Erik Huleg årdh, Hege Garelius, Lars Möllgård, Mats Brune, Anders Wahlin, Stig Lenhoff, Ulla Frödin, Mats Remberger, Martin Höglund, Gunnar Juliusson, Dick Stockelberg, Sören Lehmann Source Type: research